Try our Advanced Search for more refined results
Life Sciences - July, 2021
328 articles
- Pa. Health Network Says Virus Losses Covered By Policy
- J&J Wins Ill. Talc Cancer Trial Despite Contempt Finding
- Inovio Investors Move For Cert. In COVID-19 Vaccine Suit
- 6th Circ. Backs Mich. Cannabis Co. Owner's 15-Year Sentence
- Anthem Sued Over Alleged Refusal To Cover Spinal Device
- FTC Drops AndroGel Antitrust Case Against AbbVie
- McKesson Wants Prescription Data In Cherokee Opioid Case
- Illinois Hospitals' Merger Would Stifle Competition, Suit Says
- Australian Judge Makes Bold Patent Leap For AI Inventions
- Ashby & Geddes' Appeal In Del. Bankruptcy Fee Row Tossed
- Texas Pharmacist's FCA Suit Against Walgreens Thrown Out
- Health Hires: Polsinelli, Buchalter, Allen & Overy
- Biggest Merger Review Developments Of 2021 So Far
- A Potential Shift In Antitrust Deferred Prosecution Agreements
- Court Sets Terms For Pfizer Damages Over Axed Lyrica IP
- Imerys Ch. 11 Tort Group Delays J&J Talc Claim Spinoff Fight
- McKinsey Opioid MDL Has A Need For Speed, Judge Says
- IP Forecast: Fed. Circ. To Mull Narcan Patents
- Regeneron Investor Sues Execs, Alleging Kickback Scheme
- Purdue Pharma Gets OK For $22M Worker Bonus Program
- 11th Circ. Tosses Ala. Dental Board's SmileDirect Appeal
- Deals Rumor Mill: Baxter International, Didi Global, Nanosys
- Novartis Cancer Drug Suits Too Few To Centralize, JPML Told
- Senate Panel OKs Antitrust Package Aimed At Drug Pricing
- WTO Sees Trade Rebound Hinging On Vaccine Rollout
- Will You Be Ready If Your Class Action Goes To Trial?
- Biden Admin. Agrees To Crack Down On Upwind Air Pollution
- JPML Urged To Consolidate Weight-Loss Drug Cancer Suits
- Sustainable Biomanufacturing Co. Grabs $100M In Series B
- Three Firms Fined £100M For Overpriced Thyroid Drug
- Opioid Distributors Pin Blame On Others As W.Va. Trial Ends
- Endo, Arnold & Porter Accused Of Cover-Up In Opioid MDL
- Vaxart Suit Turns 'Mundane To Nefarious,' Del. Judge Told
- In Praising O'Malley, Attys Call For District Judge To Fill Seat
- McKinsey Says Cherokee Opioid Suit Can't Go To State Court
- 'Momentous Day' As FDA OKs 1st Interchangeable Biosimilar
- Agenus Investor Sues In Del. Chancery Over Option Awards
- 3 Firms Seek $1.3M In Fees From Zynerba CBD Gel Settlement
- House Subcommittee Asks J&J About Talc Bankruptcy Plans
- P&G Seeks To End Crest Charcoal Toothpaste Class Action
- Amgen's Psoriasis Drug Patents Are Valid, NJ Court Told
- Tide Is Turning Against FCA Case Dismissals
- Law Firms, Know Who's Responsible For Your Cloud Security
- McCarter & English Keeps Win In $860K Fee Suit
- Imerys Seeks Talc Indemnification From Johnson & Johnson
- Houston Energy Exec Pleads Guilty In $317M N95 Scam
- 4 Key Details As Opioid Liability Trial Concludes In Calif.
- 'Mountainous' Opioid Shipments Fed Crisis, Judge Told
- Monsanto Hit With $185M Verdict Over PCB Brain Damage
- FCA Overhaul Bill May Miss Mark On Reining In Fraudsters
- That's A Rap: Shkreli's Wu-Tang Album Sold To Cap Judgment
- Illumina Wants Extra Witnesses For FTC Merger Challenge
- Bio-Rad And 10X Agree To End Patent War
- Benefits For Law Firms Venturing Into New Services
- Arthrex Asks To Fight PTAB Ax On Other Grounds On Remand
- Why Bypass Continuation Is Best For Nat'l Phase Patent Entry
- Johnson & Johnson Held In Contempt In Illinois Talc Trial
- Look To Canada For Cheaper Drugs, Sens. Urge Biden Admin.
- Philips Faces Class Suits Over Recalled CPAP Sleep Devices
- Judge Urged To Rethink Ruling Perrigo Hid $1.9B Irish Tax Bill
- Purdue Pharma Reports Glowing Vote Results For Ch. 11 Plan
- McKinsey Sued For Opioid Effect On W. Virginia Addicts' Kids
- Biotech Co. Can't Arbitrate $881M Cannabinoid IP Fight
- Mall Developer's Asbestos Caused Cancer, Calif. Judge Told
- Takeda Beats Antitrust Claims In Heartburn Drug Patent Fight
- DEA Should Allow Psychedelic Therapy, 9th Circ. Told
- Review Group Slams 'Specious' Sun Pharma Skin Drug Patent
- Hologic Gets Minerva Patent Axed Just Before Del. Trial
- Bipartisan Senator Group Wants False Claims Act Tweaks
- Pfizer, Mylan Beat EpiPen Antitrust Suit, For Now
- SmileDirect Tells 9th Circ. Dental Board Fears Shakeup
- PBM Group Asks 8th Circ. To Revive ND Preemption Row
- Price-Fix 'Common Thread' Links Glenmark To Teva, DOJ Says
- NM Appeals Court Backs Award Of Medical Pot License
- Quartet Of Life Sciences Cos. Prepare For $526M In IPOs
- New FTC Mergers Approach Raises Risks For Buyers, Sellers
- Massage Oil Co. Drops Indemnity Bid In Class Action Fight
- DOJ Fights Walmart's Opioid Challenge At 5th Circ.
- Embracing ESG: Exelon GC Talks Diversity Initiatives
- Buchalter Adds 2 Attorneys To Orange County Office
- Allergan Hits Generic Cos. With Patent Suits Over Viberzi
- 3 Firms Sculpt PerkinElmer's $5.25B Buy Of Life Sciences Co.
- Where Have All The Associates Gone?
- The Law360 400: Tracking The Largest US Law Firms
- US Drops 5 Visa Fraud Suits Against Chinese Scholars
- Opioid Wholesalers, W.Va. Gov'ts Set To Wrap Bellwether
- Cannabis Bill Roundup: Amazon Becomes Pot Lobbyist
- Regeneron 'Kickbacks' Fueled Blockbuster Profits, Suit Says
- Shuttered Mo. Medical Pot Co. Ordered To Pay Back Investors
- Product Liability Regs, Bills To Watch In The 2nd Half Of 2021
- FCA Relator Pursuit Of DOJ's Declined Cases Is Vital
- 3rd Circ. Affirms Win For Novo Nordisk On Age Bias Suit
- UK Litigation Roundup: Here's What You Missed In London
- End Roe V. Wade, Justices Urged As Abortion Battle Begins
- Dems Want Social Media Cos. Liable For Vax Misinformation
- Gilead Must Foot $1.8M Bill For 'Egregious' Litigation Conduct
- Chinese Medical Co. Beats Sleep Apnea Trade Secrets Fight
- EU Deepens Probe Of Illumina's $8B Cancer Detection Deal
- DC Circ. Affirms FDA Fees, Premarket Review Of Pipes, Cigars
- CR Bard Nets 2 Wins, 1 Loss In Faulty IVC Filter Suits
- Drugmaker Acer To Pay $8.35M To End Investor Suit
- Philly DA Slams Opioid Settlement As A Sellout For City
- Attys Seek $11.5M For Fighting Fresenius' 'Stalingrad' Defense
- Anticipating The FDA's Shift Away From Emergency Approvals
- Endo Offers To End Tenn. Opioid Baby Suit For $35M
- Judicial Nominees Advance As GOP Knocks 1st Circ. Pick
- House OKs Bill To Join Health Coalition Funding Vaccines
- Jury Hits Novartis With $178M Verdict In Drug Patent Fight
- Kirkland-Led Insurer Ryan Specialty Lands $1.3B IPO
- Revamping Law Firm Marketing Lists — With Partner Buy-In
- Pfizer Unit Loses Appeal In Vaccine Fight With Merck Branch
- Pump Maker Loses Bid To Appeal Roche's UK Patent Win
- Despite Fanfare, $26B Opioid Offer Far From Finish Line
- Daiichi Sankyo Unit Seeks $178M From Novartis As Trial Ends
- Illumina 'Wasting Court Time' With Deal Overtures, FTC Says
- J&J Settles Pfizer's Antitrust Suit Over Remicade Biosimilar
- Health Co., Investor Ink $15.3M Deal To End DOJ Fight
- Flopped COVID Drug Trial Spurs Corporate Waste Suit
- 5th Circ. Mulls New Trial Bid In Sanofi Chemo Bellwether
- UMass Tells Fed. Circ. To Wipe Out L'Oreal's Skincare IP Win
- Shook Hardy Names 3 New Office Leaders Amid Expansion
- Takeda 401(k) Suit 'Squeaks By' Dismissal, Judge Says
- Pharmacist Gets More Prison In Deadly Meningitis Outbreak
- AGs Unveil $26B Global Opioid Deal With J&J, Distributors
- NY Official Tells Jury Public Was Taught To Treat Opioid ODs
- House Hearing Slams Opacity Of FCC Spectrum Rulemaking
- Opana Sales Calls Didn't Cause Rx Rise, Economist Testifies
- Utah Medical Pot Licenses Unlawfully Awarded, Suit Says
- House Votes To Restore FTC Disgorgement Authority
- 'Lives Are On The Line,' Say GOP Reps Pushing Biden On Pot
- Fidelity Dodges Pfizer Retiree's Suit Over Lack Of Tax Advice
- DC Circ. Won't Add To Novo Nordisk Whistleblower's Payout
- NY Urges Justices To Pass On State Opioid Tax Challenge
- The Murky World Of Legal Rankings Gets Some Clarity In NJ
- Judge OKs Consolidation Of CVS Drug Pricing Suits
- Examiner Clears Sacklers Of Influencing Purdue's Board
- Baker Botts Adds Tech Partner To Dallas Corporate Practice
- Drug Distributors Strike $1.1B Opioid Deal, Exit NY Trial
- Husch Blackwell Moves Into New England With 11-Atty Firm
- J&J, Distributors Set To Unveil Opioid Deals Worth $26B
- US Trustee Flags Sacklers' Release, Atty Fees In Purdue Plan
- Novartis IP Expert Slams Rival's Royalties Estimate At Trial
- FDA-Nixed Language Can Be In Drug Promos, Expert Testifies
- Galderma Gets PTAB To Invalidate Wrinkle Treatment Patent
- Talc Plaintiffs' Attys Fume At Idea J&J Might Use Ch. 11 Tactic
- Optical Lab Wants Black Ex-Worker's Bias Suit Tossed
- Indiana Univ. Can Keep COVID Vax Requirement During Suit
- FDA Q2 Warning Letters Show Agency Enforcement Priorities
- Embracing ESG: Cigna Counsel Talks Employee Wellness
- Ex-FDA Senior Regulatory Counsel Joins Foley Hoag In DC
- Novartis' Expert Denies Rival Atty's Plagiarism Claim In IP Trial
- Invisalign Maker, Investors Hatch $16M Deal In IP-Linked Suit
- AstraZeneca's Anemia Drug Sees Setback At FDA Committee
- Bankruptcy Cases To Watch In The Second Half Of 2021
- McKinsey Says Cherokee Opioid Suit Destined For MDL
- Apotex Pays Texas $26M To End Medicaid Fraud Probe
- POP Won't Review PTAB Institution Rulings On Align Patents
- Hybrid Work Models Are Key To Gender Parity In Law Firms
- Perrigo's Investor Form In $1.9B Tax Row Ruled Misleading
- Pa. Judge Defends Financial Discovery In Vein Filter Litigation
- Jones Day Adds Consumer Products Counsel In Miami
- UK Litigation Roundup: Here's What You Missed In London
- Novartis' Expert Accuses Rival's Atty Of Gaslighting In IP Trial
- Opioid Cos. Defied FDA Promo Limits, Ex-Commissioner Says
- McKesson's 'Abusive Discovery' Is FCA Dismissal Ploy: DOJ
- Naturopathic Doc Sold Fake COVID Vaccine Cards, Feds Say
- J&J Sued Over Carcinogen After Sunscreen Recall
- Club Operator's $420M Float Leads Busy Day Of IPOs
- IP Forecast: Alsup To Hear Finjan's Fee Fight With Juniper
- PTAB Will Review Alzheimer's Treatment Patent
- Pfizer And EpiPen Consumers Reach $345M Deal
- Digging Into FCA Stats: Litigation's Return On Investment
- Sea Change In Drug Assistance Programs May Be On Horizon
- 6 Things To Know About Cannabis M&A Transactions
- USPTO Says US Inventor's Fintiv Loss Also Hurts Tech Suit
- Biopharma Co. Says Unnamed Person Is Impersonating CEO
- A Practical Metric For Annual Patent Filing Targets: Part 3
- Fed. Circ. Calls For New Damages Trial In Pet IP Row
- Novartis Shorted Rival Up To $47M In IP Royalties, Jury Told
- Loeb & Loeb Swipes PTAB Pro From Womble Bond
- Perrigo, Investors Must Go To Trial Over Co.'s $1.9B Tax Bill
- AstraZeneca Wins Final Nod For $39B Alexion Deal
- Suzanne Somers' Sabotage Trial Against QVC Set For Fall
- 3 Keys To Winning Your Next Oral Argument
- Digging Into FCA Stats: A Decade of Litigation Trends
- 7th Circ. Orders Judge Consider Copay Groups In Opana Cert.
- Pfizer Unit Fights Loss To MSD In Pneumonia Vaccine IP Case
- WHO Committee Wants Global Rules On Gene-Editing Patents
- Top Senate Dems Admit Pot Legalization Push A Long Shot
- Former In-House Global IP Head Pivots To Smith Gambrell
- Dickinson Wright Adds 7 Attys To IP Practice
- 3 Takeaways From Senate Dems' Pot Legalization Bill
- DuPont, Others Ink $50M Del. Deal Over 'Forever Chemicals'
- Judge Tells Attys IP Testimony Is 'Dense,' But 'It's Your Case'
- Traps, Thickets And Hops: Sens. Pin Down Drug Price Culprits
- J&J Win In Asbestos-Talc Case Meets Skeptical Appeals Panel
- Opioid Rx Rise Can't Be Pinned Only On Ads, Prof Says
- We Can Dance If We Want To, We Can Put Our Patents Online
- Doctors Were Engine Of Opioids' Rise, Cos. Tell Jury
- Cherokees Say McKinsey Opioid Suit Shouldn't Head To MDL
- PTAB Won't Review Amgen Patent On Chemotherapy Drugs
- What To Watch As EU Clinical Trial Compliance Changes
- Teva Says Rival Hoarding Drug To Slow Generic Development
- Digging Into FCA Stats: In-House Litigation Budget Insights
- PE-Backed Waterworks Co. Leads 4 IPOs Likely To Top $1.2B
- Israeli Co. Fights Arbitration Of $16M Sex Discrimination Suit
- Pharma Co. Asks 9th Circ. To Revive Opioid Coverage Dispute
- J&J, Rite Aid, CVS Talc Suit Remanded To NY State Court
- Fed. Circ. Told 10X's IP Loss At Odds With Minerva Ruling
- Keys To Efficient And Accurate Doc Review For E-Discovery
- Roche Invalidates Competitor's Insulin Pump IP In UK Suit
- Wilson Sonsini Adds Ex-Shearman & Sterling Atty In Texas
- Meet JPML's Favorite Judge, Tasked With New Opioid MDL
- Opioid Cos.' Sales Training Misled Doctors, Jury Hears
- Daiichi Sankyo Unit Says Rival Infringed IP As Trial Opens
- Insurer Leads Flood Of 14 IPO Prospects That Could Top $3B
- Chickasaw Push Back On Arbitration Ruling In Drug Dispute
- Venable Adds 5 Intellectual Property Partners From Dentons
- HHS Funding Bill Passes Through House Subcommittee
- US Trustee Calls For Hold On $29M In Purdue Bonuses
- Avoiding Antitrust Issues In Search Term Ad Agreements
- Embracing ESG: Raytheon GC Talks Climate Change
- Insulin Drug Makers Shed Antitrust Claims In MDL
- Kirkland Nabs Litigator From Orrick In DC
- Top New Jersey Cases Of 2021: A Midyear Report
- Allergan Strikes $130M Deal Over Drug Price-Fixing Claims
- Humanigen, Savant Dispute Over Drug Development Narrowed
- Shaming Doctors Was Vital To Opioid Adoption, NY Jury Hears
- Gov't Can't Ditch Akebia's Suit Over Kidney Drug Coverage
- Drug Prices Are Prime Target In Biden's Competition Order
- Cannabis Bill Roundup: Missouri Gov. Nixes Pot Tax Reform
- FDA Head Seeks IG Probe Of Biogen Alzheimer's Drug Talks
- Big Pharma's Stock Spending Exceeds R&D, Dems Say
- Health Hires: SCAN Group, AgomAb
- Jury Awards Utica Mutual $10.9M In Asbestos Reinsurance Rift
- Changes In Over-The-Counter Drug Regulation Are Flawed
- J&J Can't Block Deposition Of Media Rep In Talc Cancer Suit
- 9th Circ. Won't Revive Ex-Merck Worker's Drug Kickback Suit
- Bayer, Janssen Duck Louisiana Blue Cross' Xarelto Claims
- Pa. Cases To Watch In 2021: Midyear Report
- Former Dow Counsel, Ex-EPA Exec Joins Barnes & Thornburg
- High Court Arthrex Remedy Should Concern Congress
- Atty Joins Gordon & Rees As Partner In NJ And NY Offices
- Taxation With Representation: Gibson, Latham, Simpson
- Generics, Retailers Escape Zantac MDL With Preemption
- Real Estate Rumors: Foundry, Raytheon, RAS Development
- EPA Revokes Allied BioScience SurfaceWise2 Spray Approval
- Product Liability Cases To Watch: Midyear Review
- Sweeping Biden Order Aims To Attack Lack Of Competition
- Evoqua To Pay $16.7M To End Investors' Suit Over $500M IPO
- Opioid 'Gremlins' Torment Patients, New York Jury Hears
- Alere Agrees To Pay $38.8M Over Blood Monitoring Device
- St. Jude Medical To Pay $27M To End Faulty Heart Device Suit
- USPTO Opens Floodgates To Patent Eligibility Feedback
- Stryker Cos. Will Pay $15M To End Medical Device Patent Suit
- Fed. Circ. Appears Split On Novartis' MS Drug Patent
- IP Forecast: Daiichi Sankyo Unit Takes Drug Rival To A Jury
- Avanos To Pay $22M To Settle Surgical Gown Criminal Charge
- 5th Circ. Backs Broad DOJ Power To Toss FCA Suits
- Alzheimer's Drug Getting Label Revision, Biogen Says
- 5 Firms Steer PE Sale Of €1.25B Genetic Testing Co
- Nationwide Sues To Avoid Defending Vitamin Co. In TM Fight
- Deals Rumor Mill: Sydney Airport, Tencent, Ottobock
- Withers Picks Red-Hot Kendall Square For New Mass. Office
- Responding To Novelty Rejections After Recent PTAB Ruling
- Rising Star: Covington & Burling's Tyler Evans
- 1-800 Contacts Ruling Illustrates IP Hurdle For Antitrust Cases
- 5 Firms Sculpt SPAC Deal For $1B Tumor Treatment Developer
- Judge Blasts J&J Unit For 'Tactical' Silence In Drug IP Fight
- 15 States Sign On To $4.5B Opioid Deal With Purdue
- Ex-JHL Biotech Execs Charged In $101M Wire Fraud Scheme
- Calif. Coroners Testify Opioid Death Causes Can Be Unclear
- NY Opioid Trial Dives Into History On 4th Day
- Theranos Judge Mulls WilmerHale's Role In Losing Key Data
- Boston Marriott Won't Get Early Win In Virus Coverage Row
- COVID Vaccine Vial Maker Leads Wave Of 5 IPO Launches
- McKool Smith Adds 2nd IP Litigator From Paul Hastings
- DC Circ. Won't Revisit Health Costs Ruling In Swinomish Suit
- Ethicon Says Fla. Pelvic Mesh Suit Was Filed Too Late
- NM AG's Suit Against Gilead, BMS Sent Back To State Court
- 5 Patent Cases To Watch In The Second Half Of 2021
- Pharmacist Linked To Deadly Outbreak Gets Extra 5 Years
- Rising Star: King & Spalding's Marisa Maleck
- Mass. Ruling A Cautionary Tale For Attorneys Changing Firms
- DOJ Should Weigh Dismissing Every Nonintervened FCA Suit
- Polish Drug Co. Says Trade Secret Fight Belongs In Arbitration
- Fed. Circ. Judge Unsure IP At Heart Of $1.1B Juno Win Is Valid
- Ill. Kickback Ruling Must Be Reconsidered, Court Told
- EU Remains A Holdout On COVID-Related IP Waiver At WTO
- The Term Finale: A 'Kumbaya Court'? Not So Fast
- Jones Day, Milbank Steer $1.7B Huntington Ingalls, Alion Deal
- DC Circ. Tosses FDA's Electric Shock Harnesses Ban
- Banner Witcoff Lands An IP Trial Pro From Morgan Lewis
- CMS Must Improve Diabetics' Access To Glucose Monitors
- The Biggest Patent Rulings Of 2021: A Midyear Report
- Rising Star: Kirkland & Ellis' Devora Allon
- The Sharpest Dissents From The Supreme Court Term
- Returning To Open Court: Excitement, Nerves And Extra Prep
- 3 Firms Build PE Swap For $5.25B Water Treatment Biz Solenis
- The Firms That Won Big At The Supreme Court
- Jury Convicts Medical Imaging CEO In $250M Health Fraud
- Brand Battles: Zynga Aims To Beat New 'With Friends' Game
- Miss. High Court Won't Reconsider Medical Pot Ruling
- Cannabis Bill Roundup: NC Advances Medical Pot Bill
- WTO Stresses Need For Better COVID-19 Trade Reporting
- Glenmark Wants Criminal Price-Fix Trial Cut Off From Teva's
- Justices Seemed Above The Political Fray, Until The Last Day
- Teva Sues Generics To Protect Huntington's Disease Drug
- Next Steps For Cos. After High Court Patent Assignor Ruling
- Rising Star: Skadden's Chadé Severin
- Orrick Nabs Ex-MoFo Life Sciences Atty In Silicon Valley
- CVS Persuades Justices To Review HIV Bias Case
- UK Litigation Roundup: Here's What You Missed In London
- Justices Agree To Review Medicare Reimbursement Programs
- Simpson, Kirkland Drive PE Purchase Of $8.5B Parexel
- How To Avert Media Narrative And Get A Fair High-Stakes Trial
- Servier Beats NHS' £220M Drug IP Suit At Top UK Court
- Retailers, Pharmacies Freed From Zantac Personal Injury MDL
- 1 Firm Edged Peers As June IPO Market Exploded
- Fed. Circ. Forecast: Kite Takes Aim At Juno's $1.2B IP Win
- Samsung Gets PTAB To Nix Image Sensor Patent Claims
- Fla. Employer Doesn't Have To Pay For Medical Pot Evaluation
- House Votes To Shield IGs, Allow Probes Of DOJ Attys
- A New Era For FDA Regulation Of Cell And Tissue Products
- Coronavirus Regulations: A State-By-State Week In Review
- Ad Dispute Process Does Not Boost Class Action Risk
- Breaking Down The Vote: The High Court Term In Review
- 6 Firms Assist As MKS Inks $6.5B Atotech Acquisition